Report of Foreign Issuer (6-k)
June 29 2017 - 5:29PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 6-K
Report of Foreign Private Issuer
Pursuant to Rule 13a-16 or 15d-16
under the Securities Exchange Act of 1934
June 2017
Commission file number: 001-36288
Akari Therapeutics, Plc
(Translation of registrant’s name into English)
24 West 40
th
Street, 8
th
Floor
New York, NY 10018
(Address of principal executive offices)
Indicate by check mark whether the registrant files or will
file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F
x
Form
40-F
¨
Indicate by check mark if the registrant is submitting the Form
6-K in paper as permitted by Regulations S-T Rule 101(b)(1):_____
Indicate by check mark if the registrant is submitting the Form
6-K in paper as permitted by Regulations S-T Rule 101(b)(7):_____
CONTENTS
On June 28, 2017, an
Annual General Meeting of Shareholders of Akari Therapeutics, Plc. (the “Company”) was held. At the meeting, all proposals
brought before the Company’s shareholders were approved in accordance with the majority required for each proposal, with
the exception of proposal no. 10, which was not put to a vote at the meeting. Each of those proposals was described in the Company’s
Notice of Annual General Meeting of Shareholders, dated May 15, 2017, and in its Proxy Statement, dated May 15, 2017, attached
as Exhibit 99.1 to the Company’s Form 6-K that was furnished to the U.S. Securities and Exchange Commission on
May 16, 2017.
The information contained
in this report (including the exhibits hereto) is hereby incorporated by reference into the Company’s Registration Statement
on Form S-3, File No. 333-207443, Form S-8 (No. 333-198109 and 333-207444), Registration Statement on Form F-3 File No. 333-198107,
and the Registration Statements on Post-Effective Amendments to Form F-1 on Form F-3 (333-185247, 333-187826 and 333-191880).
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act
of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
|
Akari Therapeutics, Plc
|
|
|
(Registrant)
|
|
|
|
|
|
|
|
|
|
|
By:
|
/s/ Robert M. Shaw
|
|
|
Name:
|
Robert M. Shaw
|
|
|
|
General Counsel & Secretary
|
|
Date: June 29, 2017
Akari Therapeutics (NASDAQ:AKTX)
Historical Stock Chart
From Mar 2024 to Apr 2024
Akari Therapeutics (NASDAQ:AKTX)
Historical Stock Chart
From Apr 2023 to Apr 2024